장기지속형 주사제 시장 : 적응증별, 분자 유형별, 투여 경로별, 디바이스 형태별, 제제 기술별, 환자 유형별, 최종사용자별, 유통 채널별, 지불자별, 지역별

Long Acting Injectables Market is estimated to be valued at USD 21.71 Bn in 2026 and is expected to reach USD 52.03 Bn by 2033, growing at a compound annual growth rate (CAGR) of 13.3% from 2026 to 2033.

The global long acting injectables market represents a rapidly evolving segment of the pharmaceutical industry, characterized by innovative drug delivery systems designed to enhance patient compliance and therapeutic outcomes. Long acting injectables (LAIs) are specialized pharmaceutical formulations administered via intramuscular, subcutaneous, or other injection routes, providing sustained drug release over extended periods ranging from weeks to months. These advanced delivery mechanisms eliminate the need for frequent dosing, addressing critical challenges associated with medication adherence, particularly in chronic conditions such as schizophrenia, bipolar disorder, diabetes, and HIV treatment.

The market encompasses various technological platforms including microspheres, liposomes, implants, and depot formulations, utilizing sophisticated drug delivery technologies to achieve controlled and sustained therapeutic effects. The growing prevalence of chronic diseases, increasing focus on patient-centric healthcare solutions, and rising demand for personalized medicine are driving significant investments in LAI research and development. Pharmaceutical companies are increasingly recognizing the commercial potential of long acting formulations, as they offer competitive advantages through improved patient outcomes, reduced healthcare costs, and enhanced market differentiation. The market landscape is characterized by complex manufacturing processes, stringent regulatory requirements, and substantial research and development investments, positioning LAIs as a critical component of modern therapeutic strategies across multiple disease areas.

Market Dynamics

The global long acting injectables market is propelled by several key drivers that are fundamentally reshaping pharmaceutical treatment paradigms and patient care approaches. The primary growth driver stems from the critical need to address medication non-adherence, which affects approximately 40-60% of patients with chronic conditions, resulting in billions of dollars in healthcare costs and compromised therapeutic outcomes. Long acting injectables offer a compelling solution by ensuring consistent drug delivery and eliminating daily dosing requirements, particularly benefiting patients with psychiatric disorders, diabetes, and infectious diseases. The increasing prevalence of chronic diseases, aging global population, and growing awareness of personalized medicine are creating substantial market opportunities for LAI manufacturers.

However, the market faces significant restraints including high development costs, complex manufacturing processes, and stringent regulatory approval pathways that can extend development timelines by several years. The technical challenges associated with formulation stability, injection site reactions, and dose flexibility limitations also present barriers to market expansion.

Additionally, higher initial treatment costs compared to oral medications and limited physician familiarity with LAI administration techniques can impede adoption rates. Despite these challenges, the market presents remarkable opportunities through technological advancements in drug delivery systems, expanding applications across therapeutic areas, and increasing healthcare focus on value-based care models. The emergence of biodegradable polymers, nanotechnology-based delivery systems, and combination therapy approaches are creating new avenues for market growth, while growing investments in emerging markets and increasing healthcare infrastructure development are opening additional revenue streams for industry participants.

Key Features of the Study

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global long acting injectables market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Eli Lilly and Company, Novo Nordisk A/S, Janssen Pharmaceuticals (Johnson and Johnson), AstraZeneca, Pfizer Inc, GlaxoSmithKline plc, ViiV Healthcare, Merck and Co Inc, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Ltd, Sanofi, Boehringer Ingelheim, Amgen Inc, Roche, and Sun Pharmaceutical Industries
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global long acting injectables market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global long acting injectables market

Market Segmentation

• Indication Insights (Revenue, USD Bn, 2021 - 2033)
• Psychiatric disorders
• Neurological disorders
• Endocrine and metabolic disorders
• Infectious diseases
• Women's health
• Oncology and supportive care
• Pain, addiction and CNS supportive care
• Other chronic diseases
• Molecule Type Insights (Revenue, USD Bn, 2021 - 2033)
• Small-molecule drugs
  • Antipsychotics
  • Hormonal agents (e.g., contraceptives)
  • Analgesics and addiction therapies
  • Other small-molecule LAIs
• Peptides and peptide analogues
  • GLP-1 and related incretin mimetics
  • Other therapeutic peptides
• Proteins and biologics
  • Monoclonal antibodies
  • Fusion proteins and recombinant hormones
  • Long-acting growth factors and cytokines
• Nucleic acid-based and gene-modifying agents
  • Oligonucleotides
  • Gene therapy-linked depot systems
• Vaccines and immunotherapies in LAI formats
• Other molecule types
• Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
• Intramuscular (IM)
• Subcutaneous (SC)
• Intravitreal
• Intra-articular
• Intrathecal and epidural
• Other specialized parenteral routes
• Device Format Insights (Revenue, USD Bn, 2021 - 2033)
• Pre-filled Syringes
• Auto-injectors
• Vial and Syringe Kits
• Implant Kits
• Pen-injector LAI Systems
• Formulation Technology Insights (Revenue, USD Bn, 2021 - 2033)
• Microsphere-based Depots
• In-situ Forming Depots
• Liposomal LAIs
• Nano-suspensions
• Polymer-conjugated LAIs
• Implantable LAI Devices
• Oil-based Injectable Depots
• Long-acting Injectable Crystalline Suspensions
• Patient Type Insights (Revenue, USD Bn, 2021 - 2033)
• Adult
• Geriatric
• Pediatric
• End User Insights (Revenue, USD Bn, 2021 - 2033)
• Hospitals
• Specialty Clinics
• Community Health Centers
• Ambulatory Surgical Centers
• Home-care/Self-administration Programs
• Government and Public Health Programs
• Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• Payer Insights (Revenue, USD Bn, 2021 - 2033)
• Public
• Private
• Regional Insights (Revenue, USD Bn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
• Eli Lilly and Company
• Novo Nordisk A/S
• Janssen Pharmaceuticals (Johnson and Johnson)
• AstraZeneca
• Pfizer Inc
• GlaxoSmithKline plc
• ViiV Healthcare
• Merck and Co Inc
• Takeda Pharmaceutical Company
• Teva Pharmaceutical Industries Ltd
• Sanofi
• Boehringer Ingelheim
• Amgen Inc
• Roche
• Sun Pharmaceutical Industries

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Long Acting Injectables Market, By Indication
  • Global Long Acting Injectables Market, By Molecule Type
  • Global Long Acting Injectables Market, By Route of Administration
  • Global Long Acting Injectables Market, By Device Format
  • Global Long Acting Injectables Market, By Formulation Technology
  • Global Long Acting Injectables Market, By Patient Type
  • Global Long Acting Injectables Market, By End User
  • Global Long Acting Injectables Market, By Distribution Channel
  • Global Long Acting Injectables Market, By Payer
  • Global Long Acting Injectables Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Long Acting Injectables Market, By Indication, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Psychiatric disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Neurological disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Endocrine and metabolic disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Infectious diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Women's health
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Oncology and supportive care
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Pain, addiction and CNS supportive care
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Other chronic diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

5. Global Long Acting Injectables Market, By Molecule Type, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Small-molecule drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • Antipsychotics
    • Hormonal agents (e.g., contraceptives)
    • Analgesics and addiction therapies
    • Other small-molecule LAIs
• Peptides and peptide analogues
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • GLP-1 and related incretin mimetics
    • Other therapeutic peptides
• Proteins and biologics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • Monoclonal antibodies
    • Fusion proteins and recombinant hormones
    • Long-acting growth factors and cytokines
• Nucleic acid-based and gene-modifying agents
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • Oligonucleotides
    • Gene therapy-linked depot systems
• Vaccines and immunotherapies in LAI formats
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Other molecule types
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

6. Global Long Acting Injectables Market, By Route of Administration, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Intramuscular (IM)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Subcutaneous (SC)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Intravitreal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Intra-articular
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Intrathecal and epidural
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Other specialized parenteral routes
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

7. Global Long Acting Injectables Market, By Device Format, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Pre-filled Syringes
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Auto-injectors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Vial and Syringe Kits
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Implant Kits
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Pen-injector LAI Systems
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

8. Global Long Acting Injectables Market, By Formulation Technology, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Microsphere-based Depots
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• In-situ Forming Depots
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Liposomal LAIs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Nano-suspensions
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Polymer-conjugated LAIs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Implantable LAI Devices
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Oil-based Injectable Depots
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Long-acting Injectable Crystalline Suspensions
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

9. Global Long Acting Injectables Market, By Patient Type, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Adult
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Geriatric
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Pediatric
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

10. Global Long Acting Injectables Market, By End User, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Specialty Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Community Health Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Ambulatory Surgical Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Home-care/Self-administration Programs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Government and Public Health Programs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

11. Global Long Acting Injectables Market, By Distribution Channel, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

12. Global Long Acting Injectables Market, By Payer, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Public
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Private
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

13. Global Long Acting Injectables Market, By Region, 2021 - 2033, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Molecule Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Device Format, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Formulation Technology, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Payer, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Molecule Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Device Format, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Formulation Technology, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Payer, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Molecule Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Device Format, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Formulation Technology, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Payer, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Molecule Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Device Format, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Formulation Technology, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Payer, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Molecule Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Device Format, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Formulation Technology, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Payer, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Molecule Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Device Format, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Formulation Technology, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Payer, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

14. Competitive Landscape

• Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novo Nordisk A/S
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Janssen Pharmaceuticals (Johnson and Johnson)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline plc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• ViiV Healthcare
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck and Co Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Takeda Pharmaceutical Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Teva Pharmaceutical Industries Ltd
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Boehringer Ingelheim
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amgen Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Roche
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sun Pharmaceutical Industries
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

15. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

16. References and Research Methodology

• References
• Research Methodology
• About us